Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	7.16B
Revenue (ttm)	829.45M
Net Income (ttm)	-1.63M
Shares Out	135.81M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,643,123
Open	56.39
Previous Close	57.71
Day's Range	52.08 - 56.67
52-Week Range	9.57 - 59.15
Beta	1.31
Analysts	Buy
Price Target	51.70 (-1.9%)
Earnings Date	Nov 25, 2025

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 1993
• Employees: 711
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR
• Website: https://arrowheadpharma.com

Financial Performance

In 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price target is $51.7, which is a decrease of -1.90% from the latest price.

Price Target

$51.7

(-1.90% downside)

Analyst Consensus: Buy